Inyx, Inc.’s wholly owned U.K. subsidiary (Ashton Pharmaceuticals Ltd.) has been selected by a leading Indian specialty pharmaceutical company to manufacture a range of generic drugs for the United Kingdom and other European countries.
Initially, Ashton will provide process transfer services to enable production of the tablet products at commercial batch sizes and then will manufacture and package the entire range of genetic products.
Jack Kachkar, M.D., Chairman of Inyx, Inc., said, "We are very pleased that Inyx has been selected for the commercial production of this client's generic drugs.
This reflects Ashton's in-depth capabilities to enable clients to bring products rapidly to market."
Inyx, Inc. is a specialty pharmaceutical company with niche drug delivery technologies and products for the treatment of respiratory, allergy, dermatological, topical and cardiovascular conditions that operates through several wholly owned subsidiaries: Inyx USA Ltd., based in Manati, Puerto Rico; Inyx Pharma Ltd. and Inyx Europe Limited (which owns and operates Ashton Pharmaceuticals Ltd.) all near Manchester, England; Inyx Canada, Inc. in Toronto; and Exaeris, Inc., based in Exton, Pennsylvania (which conducts Inyx's marketing and distribution activities) and hold corporate offices in New York City.
Source: Inyx, Inc.
.jpg)
Comment Preview